ALLO vs VALN: stock comparison and AI forecast
Allogene Therapeutics, Inc. (ALLO) and Valneva Se (VALN) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ALLO Allogene Therapeutics, Inc.
- Price
- $1.09 -52.0% · 6M
- Market Cap
- $377M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
VALN Valneva Se
- Price
- $5.51 +4.2% · 6M
- Market Cap
- $551M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- VALN is 1.5 times larger than ALLO by market capitalization ($551M against $377M).
- Over the last six months VALN returned +4.2% and ALLO -52.0%.
- VALN carries 2.76 times debt per unit of equity, against 0.26 times for ALLO.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ALLO | VALN |
|---|---|---|
| Market Cap | $377M | $551M |
| P/B Ratio | 0.86x | – |
| EPS | $-0.77 | $-1.43 |
| Book Value/Share | $1.26 | – |
| Revenue/Share | – | $5.08 |
| FCF/Share | $-0.30 | $-1.27 |
Profitability & Margins
| Metric | ALLO | VALN |
|---|---|---|
| ROE | -37.9% | – |
| ROA | -30.1% | – |
| ROIC | -34.8% | -52.0% |
| Gross Margin | – | 44.6% |
| Operating Margin | -3886.1% | -35.4% |
| Net Margin | -3566.7% | – |
| EBT Margin | -3489.0% | -45.6% |
| Tax Rate | – | -2.9% |
Financial Health
| Metric | ALLO | VALN |
|---|---|---|
| Current Ratio | 10.72x | 2.38x |
| Quick Ratio | – | 1.85x |
| D/E Ratio | 0.26x | 2.76x |
| Financial Leverage | 1.26x | 3.76x |
| Interest Coverage | -6.6x | – |
| Working Capital | $308M | $152M |
Cash Flow
| Metric | ALLO | VALN |
|---|---|---|
| Operating Cash Flow | -$102M | -$114M |
| Free Cash Flow | -$103M | -$127M |
| Capital Spending | -$400K | -$13M |
| FCF/Sales | – | -25.0% |
| CapEx/Sales | – | 2.6% |
Operational Efficiency
| Metric | ALLO | VALN |
|---|---|---|
| Asset Turnover | – | 1.12x |
| Receivables Turnover | – | 16.1x |
| Inventory Turnover | – | 5.0x |
| Fixed Assets Turnover | – | 3.8x |
| Days Sales Outstanding | – | 23 days |
| Days Inventory | – | 74 days |
| Payables Period | – | 36 days |
| Cash Conversion Cycle | – | 60 days |
Income Statement
| Metric | ALLO | VALN |
|---|---|---|
| Total Revenue | – | $508M |
| Operating Income | -$180M | -$180M |
| Net Income | -$165M | – |
| R&D Expense | $123M | $218M |
| Cost of Goods Sold | – | $281M |
Dividend & Shareholder Information
| Metric | ALLO | VALN |
|---|---|---|
| Shares Outstanding | 345M | 100M |
| EPS Growth | – | -270.3% |
ALLO vs VALN: stock comparison and AI forecast
Which is bigger, ALLO or VALN?
VALN is 1.5 times larger than ALLO by market capitalization ($551M against $377M).
Which stock performed better over the last six months, ALLO or VALN?
Over the last six months VALN returned +4.2% and ALLO -52.0%.
Which one does Intratio's AI model rank higher, ALLO or VALN?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.